In the melanoma GSE91061 cohort (treated with anti-PD-L1 and anti-CTLA4 immunotherapy), patients with PR/CR had a lower risk score compared to those with SD/PD, although this difference was not statistically significant (Supplementary Figure S7C). The gene discussed is CTLA4; the disease is melanoma.